Canada

Arch Biopartners

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Arch Biopartners Safely Completes Expanded Dosing of METABLOK

Lead Product(s): LSALT peptide

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2020

Details:

Final group received the highest daily dose of Metablok tested to date for three consecutive days and met the primary endpoints of safety and tolerability.

FSD Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study

Lead Product(s): Palmitoylethanolamide

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2020

Details:

Approval to initiate a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of ultra-micronized-PEA in normal healthy volunteers.

Arch Biopartners

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies

Lead Product(s): MetaBlok

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 04, 2020

Details:

The three-day dosing of the additional eight volunteers will provide Arch supplemental dosing data, for review by the U.S. FDA, for its future Phase II trials.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Arch Biopartners

Arch Biopartners Safely Completes Expanded Dosing of METABLOK

FSD Pharma

FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study

Arch Biopartners

Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies